Clinical Trial Update: A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam. [Phase 1]

View source ↗

Summary

A Phase 1 repeat-dose study of GSK1018921 in healthy volunteers and schizophrenia patients to assess safety, tolerability, pharmacokinetics and pharmacodynamics…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• GSK1018921
• Midazolam (Midazolam)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Schizophrenia | Phase 1 | Status: TERMINATED